(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(0.12%) $82.73
(0.94%) $2.05
(-0.43%) $2 347.50
(-0.80%) $27.44
(-0.16%) $960.00
(-0.22%) $0.933
(-0.32%) $10.99
(-0.55%) $0.796
(1.56%) $93.31
0.85% € 87.95
@ €88.23
Ausgestellt: 29 Apr 2024 @ 21:46
Rendite: -0.32%
Vorheriges Signal: Apr 29 - 15:33
Vorheriges Signal:
Rendite: 0.26 %
Live Chart Being Loaded With Signals
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer...
Stats | |
---|---|
Tagesvolumen | 406 638 |
Durchschnittsvolumen | 590 212 |
Marktkapitalisierung | 20.91B |
EPS | €0 ( 2024-03-20 ) |
Nächstes Ertragsdatum | ( €-0.410 ) 2024-05-06 |
Last Dividend | €2.11 ( 2022-06-02 ) |
Next Dividend | €0 ( N/A ) |
P/E | 21.40 |
ATR14 | €2.52 (2.87%) |
Volumen Korrelation
BioNTech SE Korrelation
10 Am meisten positiv korreliert | |
---|---|
VERB | 0.95 |
OPINL | 0.946 |
BNGO | 0.944 |
VRAY | 0.944 |
AUDC | 0.942 |
NESR | 0.939 |
EGBN | 0.939 |
CNXC | 0.938 |
MAGS | 0.938 |
AGIL | 0.938 |
10 Am meisten negativ korreliert | |
---|---|
XPDB | -0.94 |
ITAQ | -0.939 |
SWAV | -0.937 |
ROCL | -0.935 |
ATEC | -0.934 |
FTPA | -0.932 |
TIOA | -0.931 |
ROC | -0.931 |
CBRG | -0.93 |
BRIVU | -0.929 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
BioNTech SE Korrelation - Währung/Rohstoff
BioNTech SE Finanzdaten
Annual | 2023 |
Umsatz: | €3.82B |
Bruttogewinn: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2023 |
Umsatz: | €3.82B |
Bruttogewinn: | €3.22B (84.29 %) |
EPS: | €3.79 |
FY | 2022 |
Umsatz: | €17.31B |
Bruttogewinn: | €12.78B (73.82 %) |
EPS: | €38.08 |
FY | 2021 |
Umsatz: | €18.98B |
Bruttogewinn: | €15.12B (79.66 %) |
EPS: | €40.63 |
Financial Reports:
No articles found.
BioNTech SE Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
First Dividend | €2.11 | 2022-06-02 |
Last Dividend | €2.11 | 2022-06-02 |
Next Dividend | €0 | N/A |
Payout Date | 2022-06-17 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | €2.11 | -- |
Avg. Dividend % Per Year | 0.15% | -- |
Score | 1.89 | -- |
Div. Sustainability Score | 9.73 | |
Div.Growth Potential Score | 2.39 | |
Div. Directional Score | 6.06 | -- |
Year | Amount | Yield |
---|---|---|
2022 | €2.11 | 0.91% |
2023 | €0 | 0.00% |
2024 | €0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.244 | 1.500 | 5.13 | 7.69 | [0 - 0.5] |
returnOnAssetsTTM | 0.0404 | 1.200 | 8.65 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0464 | 1.500 | -0.596 | -0.894 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 9.12 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00952 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 5.58 | 1.000 | 9.04 | 9.04 | [3 - 30] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 0.186 | 0.373 | [0 - 20] |
debtEquityRatioTTM | 0.0108 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.527 | 1.000 | 4.54 | 4.54 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.181 | 1.000 | 8.38 | 8.38 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 24.52 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.166 | 0.800 | -2.23 | -1.781 | [0.5 - 2] |
Total Score | 9.73 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 20.77 | 1.000 | 8.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0464 | 2.50 | -0.383 | -0.894 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 19.63 | 2.00 | 3.46 | 0.373 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 22.59 | 2.00 | 2.47 | 4.94 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 1.406 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 2.39 |
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.